A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The aim of this study was to evaluate the efficacy and tolerability of quetiapine combined with lithium or divalproex in the treatment of bipolar mania. Patients were randomized to 6 weeks of quetiapine (up to 800 mg/day) and lithium/divalproex (Li/DVP) (target trough serum concentrations of 0.7-1.0 mEq/L and 50-100 microg/mL, respectively) or placebo and lithium/divalproex. Quetiapine+lithium/divalproex treatment (n=104) showed a 2.0-point greater improvement on the primary outcome (change from baseline in Young Mania Rating Scale total score at day 21) compared with placebo+lithium/divalproex (n=96), and a 2.8-point greater difference by day 42, but the differences between groups were not statistically significant. Other efficacy measures, however, did show a statistically significant advantage in favor of quetiapine+lithium/divalproex over lithium/divalproex monotherapy at day 42. Improvement of mean Young Mania Rating Scale scores with quetiapine+lithium/divalproex was numerically but not statistically significantly greater than lithium/divalproex monotherapy in the treatment of bipolar mania. Potential reasons for the failure of quetiapine+lithium/divalproex to differentiate from placebo+lithium/divalproex treatment on the primary outcome measure and the implications of this for the treatment of mania and future studies are discussed. Overall, the combination of quetiapine with lithium or divalproex was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0209 · Cited by 922
Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424 · cited 5×
“Of the double-blind studies that have examined the efficacy of an atypical antipsychotic as add-on to a mood-stabilizing agent, four were conducted in North America: three in the USA (DelBello et al., 2002; Sachs et al., 2002, 2004) and one in the USA and Canada (Tohen et al., 2002).”
BackgroundResultInfluentialYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Self-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264 · cited 1×
“Interestingly, double-blind studies suggest that in comparison with Li, DVP, or conventional antipsychotic monotherapy, approximately 20% more patients will respond to combination therapy and 20% more will meet remission criteria over the same trial duration (Yatham, 2005; Yatham et al., 2005).”
Self-citationYatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248 · cited 8×
“…between the quetiapine and the placebo groups in this study was two points at day 21 and approximately three points at day 42 compared with a difference of four points with risperidone (Yatham et al., 2003) in another study that did not yield a significant outcome for the primary endpoint.”
BackgroundResultInfluentialSelf-citationGrunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, R., Vieta, E., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150612 · Cited by 185 · cited 1×
“For severe BP mania, current guidelines recommend as the first-line treatment option the use of mood-stabilizing agents, such as Li or DVP, in combination with an antipsychotic agent (American Psychiatric Association, 2002; Grunze et al., 2002; Keck et al., 2004; Suppes et al., 2005).”
BackgroundSelf-citationMiller, D. S., Yatham, L. N., & Lam, R. W. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1210 · Cited by 103 · cited 1×
“For example, in one study, 82% of patients with mania were being treated with antipsychotic medications in combination with a mood-stabilizing agent (Miller et al., 2001).”
BackgroundSelf-citation
Cited by
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationVieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., & Brecher, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.001 · Cited by 227
Self-citationCruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121
Self-citationOgawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0197-8 · Cited by 66
Combination Therapy for Manic Phases: A Critical Review of a Common Practice
Geoffroy, P. A., Etain, B., Henry, C., & Bellivier, F. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12017 · Cited by 47
“Only randomized, double-blind, controlled studies were included [13-34].”
Lydiard, R. B., Culpepper, L., Schiöler, H., Gustafsson, U., & Paulsson, B. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08m00659 · Cited by 23
Self-citation
Metadata
- Authors
- Yatham, L. N., Vieta, E., Young, A. H., Möller, H.-J., Paulsson, B., & Vågerö, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-07
- Volume
- 22
- Issue
- 4
- Pages
- 212-220
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2094885305
- Cited by
- 73
- References
- 7
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.